Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
-
Clinical Benefit
Substantial
The actual benefit of this proprietary medicinal product is substantial.
Clinical Added Value
minor
ESMYA offers a minor improvement in actual benefit (IAB IV) compared to leuprorelin in terms of tolerability in the pre-operative treatment of moderate to severe symptoms in uterine fibroids in adult women of childbearing potential.
Listen
